Population entropy in APP/PS1 mice is decreased in dCA1, but increased in vCA1. حسب Udaysankar Chockanathan (18510288)

Spatial stability is decreased in APP/PS1 mice in both dCA1 and vCA1. حسب Udaysankar Chockanathan (18510288)

"…<p>(A) In dCA1, stability score was significantly decreased in APP/PS1 mice relative to C57BL/6 mice (mean ± std: C57BL/6 = -0.009 ± 0.292, APP/PS1 = -0.1845 ± 0.256, p < 10⁻⁶, two-sided Wilcoxon rank-sum test, n_C57BL/6 = 295 units from 5 recording sessions, n_APP/PS1 = 167 units from 4 recording sessions). …"

<i>Syx5</i> suppression in human cells decreases copper accumulation but does not affect rate of turnover. حسب Melanie Norgate (234832)

WCESP (2 mg/ml) decreases <i>V</i>. <i>cholerae</i> cell-surface hydrophobicity. حسب Daniel B. Pederson (604306)

Decreased motor neuron survival in E18.5 GAD67-deficient (−/−) hypoglossal and phrenic motor nuclei. حسب Matthew J. Fogarty (283288)

Botulinum toxin A (3.5 U/kg) decreases dural extravasation in IoNC injured rats. حسب Boris Filipović (336089)

Retnla overexpression decreased the levels of IL-4, IL-5, and IL-13 in OVA-induced asthmatic lung. حسب Mi-Ran Lee (664596)

Acute intestinal inflammation transiently decreases frequency of colonic LP CD5⁺ B cells. حسب Yoshiyuki Mishima (842248)

Archazolid decreases the activity and expression of cathepsin B in endothelial cells. حسب Betty Luong (5738027)

ATG 5 down-regulation decreases human A53T ASYN-induced death in rat cortical neurons. حسب Maria Xilouri (264240)

Neutrophils adhered to the apical surface of polarized-MDCK cells augment AdV entry without decreasing the TER. حسب Poornima L. N. Kotha (701665)

Figure 5 from Ammonia Suppresses the Antitumor Activity of Natural Killer Cells and T Cells by Decreasing Mature Perforin حسب Joanna Domagala (21643925)

"…<p>Ammonia decreases the amount of mature perforin in NK cells. …"

pGab1 levels decreased over time in HCV-infected Huh7.5.1 cells. حسب Da-eun Nam (18927946)

IFI27 supports LCL survival. حسب Ken Sagou (1945318)

The mean values of correctly memorized foreground characters and users’ SDNN in different background line orientations. حسب Yanqun Huang (7487657)

List of Included studies. حسب Zahra Tajik (20752452)

"…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …"

The search strategy in three databases. حسب Zahra Tajik (20752452)

"…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …"

A summary of the included study characteristics. حسب Zahra Tajik (20752452)

"…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …"

NIH score. حسب Zahra Tajik (20752452)

"…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …"

List of excluded studies. حسب Zahra Tajik (20752452)

"…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …"